Yingyun Wang - Concepedia

Concepedia

Author

Yingyun Wang

Revolution Medicines (United States)ORCID

Also Known As

Der, Channing J., Jiang, Lingyan, Muonio, Karl, Yingyun Wang

109

Publications

1.3K

Citations

13

H-Index

27

Concepts

All Affiliations

Revolution Medicines (United States)Harvard University Novartis (Switzerland)Novartis (United States)Genomics Institute of the Novartis Research Foundation

YW

About

Yingyun Wang is an author at Revolution Medicines (United States) specializing in drug discovery, cancer research, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	235
2	Cell Biology	4	4	191
3	Natural Sciences	2	2	96
4	Health Sciences	1	1	72
5	Biomolecular Engineering	1	1	52

Yingyun Wang

×

14

Publications

1.3K

Citations

13

H-Index

	Year	Citations
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, Nature	2024	268
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, Cancer Discovery	2024	231
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation Jing Lü, Tatiana Zavorotinskaya, Yumin Dai, Blood	2013	161
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, Nature	2024	150
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers Pablo D. García, John L. Langowski, Yingyun Wang, Clinical Cancer Research	2014	110
Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies Matthew T. Burger, Gisele Nishiguchi, Wooseok Han, Journal of Medicinal Chemistry Hematological MalignancyMoloney Murine LeukemiaMedicinal ChemistryKinase InhibitorMedicine	2015	72
Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors Matthew T. Burger, Wooseok Han, Jiong Lan, ACS Medicinal Chemistry Letters Drug TargetPan-pim Kinase InhibitorsChemical BiologyTumor BiologyMedicinal Chemistry	2013	52
Design and Discovery of <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers Gisele Nishiguchi, Alice Rico, Huw R. Tanner, Journal of Medicinal Chemistry Drug TargetKras Mutant TumorsKinase InhibitorsChemical BiologyPharmaceutical Chemistry	2017	44
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF Wenlin Shao, Yuji Mishina, Giordano Caponigro, Cancer Research	2018	40
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic Savithri Ramurthy, Benjamin R. Taft, Robert J. Aversa, Journal of Medicinal Chemistry	2019	38

Page 1